Coya Therapeutics, Inc. (COYA): Total Assets

Annual figures by period end, from SEC filings.

$49.95M
As of 2025-12-31
$47.31M
As of 2026-06-30
+81.2%
3-year compound annual growth
2021-12-31: $4.79M2022-12-31: $8.40M2023-12-31: $41.26M2024-12-31: $44.35M2025-12-31: $49.95M$49.95M
2021-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$49.95M+12.6%2026-03-16, Balance as of period end
2024-12-31$44.35M+7.5%2026-03-16, Balance as of period end
2023-12-31$41.26M+391.5%2025-03-18, Balance as of period end
2022-12-31$8.40M+75.2%2024-03-19, Balance as of period end
2021-12-31$4.79Mn/a2023-03-29, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Coya Therapeutics, Inc. (COYA)2025-12-31$49.95M+12.6%
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$160.46M-27.2%
Bolt Biotherapeutics, Inc. (BOLT)2025-12-31$56.75M-43.0%
Adagene Inc. (ADAG)2025-12-31$78.26M-12.3%
Roivant Sciences Ltd. (ROIV)2026-03-31$5.71B+5.0%
Xenon Pharmaceuticals Inc. (XENE)2025-12-31$633.16M-20.7%
Ovid Therapeutics Inc. (OVID)2025-12-31$150.93M+63.8%
Whitehawk Therapeutics, Inc. (WHWK)2025-12-31$150.83M+114.5%
BioAge Labs, Inc. (BIOA)2025-12-31$294.89M-17.7%

Compare COYA, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗